Assoc. Prof. BANU İSKENDER İZGİ

Publication Network

Articles 19

1. Proteomic Signatures of Cellular Reprogramming in Bladder Cancer: Insights into the Acquisition of Cancer Stem-like States and Phenotypic Plasticity

Barlak B. S. R., İSKENDER İZGİ B.

Cancer Genomics and Proteomics , vol.23, no.2, pp.300-321, 2026 (SCI-Expanded, Scopus)

2. Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation

İSKENDER İZGİ B., SARIHAN M., Barlak B. S. R., AKPINAR G., KASAP M.

BMC CANCER , vol.26, no.1, 2026 (SCI-Expanded, Scopus)

3. The Active Compound Thymoquinone Alters Chondrogenic Differentiation of Human Mesenchymal Stem Cells via Modulation of Intracellular Signaling Aktif Bileşen Timokinon İnsan Mezenkimal Kök Hücrelerinin Kondrojenik Farklılaşmasını Hücre İçi Sinyal Mekanizmaları Aracılığıyla Değiştirir

Iskender B.

Medeniyet Medical Journal , vol.37, no.1, pp.1-12, 2022 (ESCI, Scopus, TRDizin)

4. Long Term Exposure to Myrtucommulone-A Changes CD105 Expression and Differentiation Potential of Mesenchymal Stem Cells

Izgi K., Sonmez M. F., CANATAN H., Iskender B.

TISSUE ENGINEERING AND REGENERATIVE MEDICINE , vol.14, no.2, pp.113-121, 2017 (SCI-Expanded, Scopus)

5. Current status in cancer cell reprogramming and its clinical implications

Izgi K., CANATAN H., Iskender B.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.143, no.3, pp.371-383, 2017 (SCI-Expanded, Scopus) Sustainable Development

6. Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A

Izgia K., Iskender B., Sakalar C., Arslanhan A., Yuksek E. H., Hizar E., et al.

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY , vol.17, no.3, pp.404-414, 2017 (SCI-Expanded, Scopus) Sustainable Development

7. Reprogramming bladder cancer cells for studying cancer initiation and progression

Iskender B., Izgi K., CANATAN H.

TUMOR BIOLOGY , vol.37, no.10, pp.13237-13245, 2016 (SCI-Expanded, Scopus) Sustainable Development

8. Integrin-Associated Focal Adhesion Kinase Protects Human Embryonic Stem Cells from Apoptosis, Detachment, and Differentiation

Vitillo L., Baxter M., Iskender B., Whiting P., Kimber S. J.

STEM CELL REPORTS , vol.7, no.2, pp.167-176, 2016 (SCI-Expanded, Scopus)

9. Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling

Iskender B., Izgi K., Hizar E., Jauch J., Arslanhan A., Yuksek E. H., et al.

TUMOR BIOLOGY , vol.37, no.6, pp.8281-8291, 2016 (SCI-Expanded, Scopus) Sustainable Development

10. Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial-mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis

Iskender B., Izgi K., CANATAN H.

MOLECULAR AND CELLULAR BIOCHEMISTRY , vol.416, no.1-2, pp.71-84, 2016 (SCI-Expanded, Scopus) Sustainable Development

11. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer

Sakalar C., Izgi K., Iskender B., Sezen S., Aksu H., Cakir M., et al.

TUMOR BIOLOGY , vol.37, no.4, pp.4467-4477, 2016 (SCI-Expanded, Scopus) Sustainable Development

12. Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?

Iskender B., Izgi K., Sakalar C., CANATAN H.

TUMOR BIOLOGY , vol.37, no.2, pp.1967-1981, 2016 (SCI-Expanded, Scopus) Sustainable Development

13. Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9

Iskender B., Izgi K., Karaca H., CANATAN H.

JOURNAL OF NATURAL MEDICINES , vol.69, no.4, pp.543-554, 2015 (SCI-Expanded, Scopus) Sustainable Development

14. Myrtucommulone-A Induces both Extrinsic and Intrinsic Apoptotic Pathways in Cancer Cells

Izgi K., Iskender B., Jauch J., Sezen S., Cakir M., Charpentier M., et al.

JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY , vol.29, no.9, pp.432-439, 2015 (SCI-Expanded, Scopus) Sustainable Development

15. Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice

Izgi K., Iskender B., Sakalar C., Arslanhan A., SARAYMEN B., CANATAN H.

EUROPEAN CYTOKINE NETWORK , vol.26, no.2, pp.46-56, 2015 (SCI-Expanded, Scopus) Sustainable Development

16. Human embryonic stem cells and microenvironment

İskender B., İzgi K., Şanlıoğlu S., Canatan H.

Journal of Clinical and Experimental Investigations , vol.5, no.3, pp.486-495, 2014 (Peer-Reviewed Journal)

17. Induced pluripotent stem cells and cell therapy

İskender B., Canatan H.

Journal of Clinical and Experimental Investigations , vol.4, no.4, pp.550-561, 2013 (Peer-Reviewed Journal)

18. Comparative Proteomic Analysis of Supportive and Unsupportive Extracellular Matrix Substrates for Human Embryonic Stem Cell Maintenance

Soteriou D., Iskender B., Byron A., Humphries J. D., Borg-Bartolo S., Haddock M., et al.

JOURNAL OF BIOLOGICAL CHEMISTRY , vol.288, no.26, pp.18716-18731, 2013 (SCI-Expanded, Scopus)

19. Human feeder cell line for derivation and culture of hESc/hiPSc

McKay T. R., Camarasa M. V., Iskender B., Ye J., Bates N., Miller D., et al.

STEM CELL RESEARCH , vol.7, no.2, pp.154-162, 2011 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 31

1. T24 Mesane Kanseri Hücrelerinin Yeniden Programlanması Sonucunda Proteom İçeriği ve Fenotipte Görülen Dramatik Değişiklikler

BARLAK B. S. R., SARIHAN M., AKPINAR G., KASAP M., İSKENDER İZGİ B.

XIX. Tıbbi Biyoloji ve Genetik Kongresi, 27 October 2025, (Summary Text)

2. Investigating the potential of drug repurposing with teriflunomide in breast cancer

İSKENDER İZGİ B., Kongur Z. S., BARLAK B. S. R., KOÇYİĞİT E., KASAP M.

ESMO Berlin 2025, England, 17 October 2025, (Summary Text)

3. Cancer cell reprogramming induces normalisation of bladder cancer cells

İSKENDER İZGİ B., BARLAK B. S. R., SARIHAN M., AKPINAR G., KASAP M.

ESMO Berlin 2025, Berlin, Germany, 17 October 2025, (Summary Text)

4. Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming

İSKENDER İZGİ B., BARLAK B. S. R., KONGUR Z. S., SARIHAN M., AKPINAR G., KASAP M.

ESMO Immuno-Oncology Congress, Geneva, Switzerland, 11 December 2024, (Summary Text)

5. Distinctive protein expression patterns in reprogrammed and ancestral bladder cancer cells

İSKENDER İZGİ B., Barlak B. S. R., SARIHAN M., Kongur Z. S., AKPINAR G., KASAP M.

International Proteomics Congress 6th Turkish National Proteomics Congress, 11 - 12 October 2024, (Summary Text)

6. Reprogramming-induced changes in protein content of bladder cancer cell line UM-UC-3.

Barlak B. S. R., SARIHAN M., Kongur Z. S., AKPINAR G., KASAP M., İSKENDER İZGİ B.

TuPA International Proteomics Congress 6th Turkish National Proteomics Congress, 11 - 12 October 2024, (Summary Text)

7. Myrtucommulone-A augments the effects of cisplatin and epirubicin through the suppression of epithelial-mesenchymal transition-related markers in cancer cells

Barlak B. S. R., İSKENDER İZGİ B.

EACR The Tumour Ecosystem: Cellular Interactions and Therapeutic Opportunities, Bergamo, Italy, 19 - 21 March 2024, (Summary Text)

8. Prospects for cell reprogramming in cancer remodelling and treatment: A special emphasis on bladder cancer.

İskender İzgi B.

2nd International Multidisciplinary Cancer Research Congress, Giresun, Turkey, 21 - 24 July 2022, vol.1, pp.2-3, (Summary Text)

9. Prospects for cell reprogramming in cencer remodelling and treatment: A special emphasis on bladder cancer.

İSKENDER İZGİ B.

2nd International Multidisciplinary Cancer Research Congress, 21 July 2022, (Summary Text)

10. Generation of Virus Integration-Free and Feeder-Free Induced Pluripotent Stem Cells from Human CD34+ Blood Cells

İskender İzgi B.

8th International Medicine and Health Sciences Researches Congress, Ankara, Turkey, 25 December 2021, pp.250-251, (Summary Text)

11. CD34+ İnsan Kanı Hücrelerinden Virüs ve Besleyici Hücreden Bağımsız Uyarılmış Pluripotent Kök Hücrelerin Üretilmesi

İSKENDER İZGİ B.

8th International Medicine and Health Sciences Researchers Congress, 25 December 2021, (Summary Text)

12. Combination treatment potentiates the effects of anti-cancer drugs by targeting epithelial-mesenchymal transition-related factors.

İSKENDER İZGİ B.

3rd International Congress on Medical Sciences and Multidisciplinary Approaches, 02 December 2021, (Summary Text)

13. Development of an autoimmune-mediated strategy for bladder cancer vaccination in mice.

İZGİ K., İSKENDER İZGİ B., ULUSOY H. B., CANATAN H.

24th Biennial Congress of the European Association for Cancer Research, 09 July 2016, (Summary Text)

14. Reprogramming bladder cancer cells for studying cancer initiation and progression.

İSKENDER İZGİ B., İZGİ K., CANATAN H.

24th Biennial Congress of the European Association for Cancer Research, 09 July 2016, (Summary Text)

15. Mesana kanseri hücre hatlarında epitel-mezenkim geçişi (EMT) mekanizmalarının araştırılması.

İSKENDER İZGİ B., İZGİ K., Hızar E., Arslanhan A., Yüksek E. H., CANATAN H.

Ulusal Moleküler Tıp Sempozyumu, 01 June 2016, (Summary Text)

16. Trans-Sinnamaldehit'in antikanser özelliğinin ve apoptotik genler üzerine etkisinin 4T1 meme kanseri hücre hattında araştırılması

Yüksek E. H., Arslanhan A., Hızar E., SARAYMEN R., İSKENDER İZGİ B., İZGİ K.

Ulusal Moleküler Tıp Sempozyumu, 01 June 2016, (Summary Text)

17. Timokinonun insan Mezenkimal Kök Hücreleri (MKH)'nin farklılaşma yetenekleri üzerindeki etkilerinin incelenmesi

Hızar E., Arslanhan A., Gültekin M., Gültekin M., Yüksek E. H., SÖNMEZ M. F., et al.

Ulusal Moleküler Tıp Sempozyumu, 01 June 2016, (Summary Text)

18. Uroplakin 3A derived peptide vaccination reduced tumor growth in bladder cancer mice model.

İZGİ K., İSKENDER B., ULUSOY H. B., SÖNMEZ M. F., CANATAN H.

3rd International Molecular Immunology&Immunogenetics Congress (MIMIC-III), Turkey, 27 - 30 April 2016, (Summary Text)

19. Decreased cytokine content in conditioned medium of hMSCs reduces the tumorigenicity in cancer cells.

İSKENDER İZGİ B., İZGİ K., ŞAKALAR Ç., CANATAN H.

3rd International Molecular Immunology&Immunogenetics Congress (MIMIC-III), 27 April 2016, (Summary Text)

20. Harnessing hMSC cytokine expression via modulating PI3K Akt pathway

İSKENDER B., İZGİ K., ŞAKALAR Ç., CANATAN H.

2nd International Congress on Stem Cell and Cellular Therapies Antalya, 15 - 18 October 2015, (Summary Text)

21. Myrtucommulone A decreases pluripotency multipotency associated marker expression in bladder cancer cells

İZGİ K., İSKENDER B., KARACA H., CANATAN H.

2nd International Congress on Stem Cell and Cellular Therapies (ICSCCT), ANTALYA, 15 - 18 October 2015, (Summary Text)

22. Myrtucommulone A treatment decreases pluripotency and multipotency associated marker expression in bladder cancer cell line HTB 9

İSKENDER B., İZGİ K., KARACA H., CANATAN H.

EACR-sponsored 3rd Anticancer Agent Development Congress İzmir, Turkey, 18 - 19 May 2015, (Summary Text)

23. Myrtucommulone A induces both extrinsic and intrinsic apoptotic pathways in cancer cells

İZGİ K., İSKENDER B., jauch j., SEZEN S., ÇAKIR M., charpentier m., et al.

EACR-sponsored 3rd Anticancer Agent Development Congress, Turkey, 18 - 19 May 2015, (Summary Text)

24. The Combination of Thymoquinone and Paclitaxel shows anti tumor activity both in vitro and in vivo through the modulation of genes involved in apoptosis cell cycle tumor suppression and growth factor cytokine activity

ŞAKALAR Ç., İZGİ K., İSKENDER B., SEZEN S., Aksu H., ÇAKIR M., et al.

EACR-sponsored 3rd Anticancer Agent Development Congress İzmir, Turkey, 18 - 19 May 2015, (Summary Text)

25. Uroplakin 3A Proteininden Türetilen Antijenik Peptidin İki farklı Adjuvanla İmmün Cevap Yanıtlarının Karşılaştırılmalı Olarak Değerlendirilmesi

İZGİ K., İSKENDER B., ŞAKALAR Ç., arslanhan a., SEZEN S., CANATAN H.

Aşı Bilimi Kongresi ve Çalıştayı, Turkey, 28 - 30 April 2015, (Summary Text)

26. Ekstrasellüler Matriks Moleküllerinin İnsan Embriyonik Kök Hücrelerin Pluripotent Özelliği Ve Farklılaşma Potansiyeli Üzerindeki Etkileri

İSKENDER B., soteriou d., byron a., humphries m. j., kimber s. j.

4. Kök Hücre Sempozyumu, İSTANBUL, TÜRKİYE, Turkey, 20 - 22 December 2013, (Summary Text)

27. Dissecting The Roles Of Extracellular Matrix Molecules In The Regulation Of Human Embryonic Stem Cell Pluripotency Clinical And Biological Implications

İSKENDER B., soteriou d., byron a., Humphries M. J., Kimber S. J.

39.Ulusal Hematoloji Kongresi-8th Balkan Day of Hematology, Turkey, 23 - 26 October 2013, (Summary Text)

28. Investigating the effects of extracellular matrix components on the regulation of pluripotency.

İSKENDER İZGİ B., Soteriou D., Byron A., Humphries J. D., Humphries M. J., Kimber S. J.

9th Annual Meeting International Society for Stem Cell Research, 15 June 2011, (Summary Text)

29. Investigating The Effects Of Extracellular Matrix Components On The Regulation Of Pluripotency

İSKENDER B., soteriou d., byron a., humphries J., humphries m., kimber s. j.

1st Annual Congress on Stem Cell Research (with International Participation), 28 September - 02 October 2011, (Summary Text)

30. Investigating The Effects Of Extracellular Matrix Components On Regulation Of Pluripotency

İSKENDER B., soteriou d., byron a., humphries J., Humphries M., Kimber S. J.

UK National Stem Cell Network 3rd Annual Scientific Conference, 12 - 14 July 2010, (Summary Text)

31. Investigating The Effects Of Extracellular Matrix Components On The Regulation Of Pluripotency

İSKENDER B., soteriou d., Humphries J., byron a., humphries m., kimber s. j.

Keystone Symposia Stem Cell Differentiation and Dedifferentiation, ABD, 15 - 20 February 2010, (Summary Text)

Books 5

Metrics

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

358

H-Index (WoS)

Citation (Scopus)

385

H-Index (Scopus)

Citation (Scholar)

549

H-Index (Scholar)

Citation (TrDizin)

H-Index (TrDizin)

Citation (Sum Other)

Project

Open Access

UN Sustainable Development Goals

Publications & Works

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Citation (TrDizin)

H-Index (TrDizin)

Citation (Sum Other)

Project

Open Access